Like most plants, soybeans pair up with soil fungi in a symbiotic mycorrhizal relationship. In exchange for a bit of sugar, the fungus acts as an extension of the root system to pull in more phosphorus, nitrogen, micronutrients, and water than the plant could on its own.
Mycorrhizal fungi occur naturally in soil and are commercially available as soil inoculants, but new research from the University of Illinois suggests not all soybean genotypes respond the same way to their mycorrhizal relationships.
"In our study, root colonization by one mycorrhizal species differed significantly among genotypes and ranged from 11 to 70%," says Michelle Pawlowski, postdoctoral fellow in the Department of Crop Sciences at Illinois and co-author on a new study in Theoretical and Applied Genetics .
To arrive at that finding, Pawlowski grew 350 diverse soybean genotypes in pots filled with spores of a common mycorrhizal fungus. After six weeks, she looked at the roots under a microscope to evaluate the level of colonization.
It was a little bit of a gamble because we didn't know much about soybean's relationship with mycorrhizae and did not know if differences in colonization among the soybean genotypes would occur. So when we screened the soybean genotypes and found differences, it was a big relief. That meant there was a potential to find genetic differences, too." Michelle Pawlowski, postdoctoral fellow in the Department of Crop Sciences at Illinois
The process of root colonization starts before fungal spores even germinate in the soil. Roots exude chemicals, triggering spores to germinate and grow toward the root. Once the fungus makes contact, there's a complex cascade of reactions in the plant that prevents the usual defensive attack against invading pathogens. Instead, the plant allows the fungus to enter and set up shop inside the root, where it creates tiny tree-like structures known as arbuscules; these are where the fungus and plant trade sugar and nutrients. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology